İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2020

What We Learned about COVID-19 So Far? Notes from Underground

Turkish Thoracic Journal

YÖKSİS OpenAlex Açık erişim · diamond SJR Q3 TR Index Atıf 9 Yüzdelik 42.2% FWCI 0.17
Yıl
2020
ISSN
2149-2530
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

The novel coronavirus pandemic poses a major global threat to public health. Our knowledge concerning every aspect of COVID-19 is evolving rapidly, given the increasing data from all over the world. In this narrative review, the Turkish Thoracic Society Early Career Taskforce members aimed to provide a summary on recent literature regarding epidemiology, clinical findings, diagnosis, treatment, prevention, and control of COVID-19. Studies revealed that the genetic sequence of the novel coronavirus showed significant identity to SARS-CoV and MERS-CoV. Angiotensin-converting enzyme 2 receptor is an important target of the SARS-CoV-2 while entering an organism. Smokers were more likely to develop the disease and have a higher risk for ICU admission. The mean incubation period was 6.4 days, whereas asymptomatic transmission was reported up to 25 days after infection. Fever and cough were the most common symptoms, and cardiovascular diseases and hypertension were reported to be the most common comorbidities among patients. Clinical manifestations range from asymptomatic and mild disease to severe acute respiratory distress syndrome. Several patients showed typical symptoms and radiological changes with negative RT-PCR but positive IgG and IgM antibodies. Although radiological findings may vary, bilateral, peripherally distributed, ground-glass opacities were typical of COVID-19. Poor prognosis was associated with older age, higher Sequential Organ Failure Assessment score, and high D-dimer level. Chloroquine was found to be effective in reducing viral replication in vitro. Likewise, protease inhibitors, including lopinavir/ritonavir, favipiravir, and nucleoside analogue remdesivir were proposed to be the potential drug candidates in COVID-19 management. Despite these efforts, we still have much to learn regarding the transmission, treatment, and prevention of COVID-19.

Konular

  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Long-Term Effects of COVID-19

Birincil konu COVID-19 Clinical Research Studies

Yazarlar

  1. FATMA TOKGÖZ AKYIL
  2. DİLEK KARADOĞAN
  3. CANAN GÜNDÜZ GÜRKAN
  4. AYCAN YÜKSEL
  5. HÜSEYİN ARIKAN
  6. TUĞBA ŞİŞMANLAR EYÜBOĞLU
  7. NAGEHAN EMİRALİOĞLU ORDUKAYA
  8. TUĞBA RAMASLI GÜRSOY
  9. İREM ŞERİFOĞLU
  10. ZEHRA NUR TÖREYİN
  11. FERİDE MARIM
  12. BİLGE YILMAZ KARA TOBB EKONOMİ VE TEKNOLOJİ ÜNİVERSİTESİ
  13. HİLAL ÖZAKINCI
  14. ELİF DEVELİ YEDİTEPE ÜNİVERSİTESİ
  15. SELİN ÇAKMAKÇI
  16. TUBA ÇİFTÇİ KÜSBECİ
  17. OĞUZ KARCIOĞLU
  18. PINAR YILDIZ GÜLHAN
  19. MERVE ERÇELİK KONCAK
  20. BERRİN ER
  21. ÖZLEM ATAOĞLU DÜZCE ÜNİVERSİTESİ
  22. DEMET POLAT YULUĞ
  23. İLKNUR KAYA
  24. TUĞBA ASLI ÖNYILMAZ
  25. ASENA AYDIN
  26. DENİZ KIZILIRMAK MANİSA CELÂL BAYAR ÜNİVERSİTESİ
  27. ASLIHAN BANU ER
  28. MUKADDES KILINÇ
  29. FATMA ESRA GÜNAYDIN
  30. SELÇUK GÜRZ ONDOKUZ MAYIS ÜNİVERSİTESİ
  31. SELEN KARAOĞLANOĞLU
  32. SELMAN ÇELİK YEDİTEPE ÜNİVERSİTESİ
  33. DORİNA ESENDAĞLI
  34. HÜSEYİN TOPTAY
  35. ÜMRAN ÖZDEN SERTÇELİK ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ
  36. METİN AKGÜN AĞRI İBRAHİM ÇEÇEN ÜNİVERSİTESİ